These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Search MEDLINE/PubMed


  • Title: Role of endogenous enkephalins in locomotion evidenced by acetorphan, an "enkephalinase" inhibitor.
    Author: Michael-Titus A, Preterre P, Giros B, Costentin J.
    Journal: J Pharmacol Exp Ther; 1987 Dec; 243(3):1062-6. PubMed ID: 3121843.
    Abstract:
    To investigate whether endogenous enkephalins modulate locomotion we studied the effect of the systemic administration of acetorphan, a parenterally active "enkephalinase" inhibitor. Locomotor activity in mice and rats was considered as an index to the activity of mesolimbic dopaminergic neurons. Acetorphan injected i.v. induced an increase in locomotion, mice and rats presenting a similar behavioral response. Naloxone, at low doses, blocked the enhanced motor response. The increased locomotion was antagonized by a pretreatment with haloperidol or potentiated by GBR 12783, a potent and specific inhibitor of dopamine (DA) uptake. The neurotoxic lesion of the mesolimbic DA system with 6-hydroxydopamine abolished the effect of acetorphan. These data suggest that the locomotor hyperactivity induced by the enkephalinase inhibitor results from the protection of local endogenous enkephalins and may be mesolimbic DA-dependent.
    [Abstract] [Full Text] [Related] [New Search]